Apixaban 5mg twice daily vs Warfarin - stroke or systemic embolism

Polypharmacy icon of two pills

APIXABAN 5MG TWICE DAILY VS. WARFARIN (TO MAINTAIN AN INR OF 2-3), NON-VALVULAR AF - STROKE OR SYSTEMIC EMBOLISM

Study population:

Patients with non valvular AF

Mean CHADS2 score 2.1

CHADS2 score > 3 (30%)

Median age 70 yrs (range 63-76)

Comments:

This means that treating 167 patients with apixaban instead of warfarin for 1.8 years might prevent one stroke or systemic embolism, and treating 67 patients with apixaban instead of warfarin for 1.8 years might prevent one major bleeding episode. Note, however, that the warfarin group were within therapeutic range only 66% of the time.

 

NNH, with respect to major bleeding, 67

 

Outcome Duration NNT Annualised NNT

Stroke or systemic embolism

1.8 years

167

301

References

Granger CB et al. Apixaban versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine 2011; 365: 981-92